Zhejiang Hisoar Pharmaceutical Co., Ltd. (SHE:002099)
China · Delayed Price · Currency is CNY 5.30
+0.09 (1.73%)
Jun 11, 2026, 1:55 PM CST
SHE:002099 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,851 | 1,851 | 1,922 | 2,163 | 2,698 | 2,477 |
Other Revenue | 10.12 | 10.12 | 16.43 | 9.14 | 6.39 | 7.99 |
| 1,861 | 1,861 | 1,938 | 2,172 | 2,704 | 2,485 | |
Revenue Growth (YoY) | -1.88% | -4.01% | -10.75% | -19.68% | 8.83% | 0.54% |
Cost of Revenue | 1,491 | 1,501 | 1,595 | 1,983 | 2,024 | 1,602 |
Gross Profit | 369.65 | 359.92 | 343.72 | 189.17 | 680.2 | 882.35 |
Selling, General & Admin | 338.12 | 327.51 | 329.6 | 345.07 | 407.92 | 563.71 |
Research & Development | 114.49 | 116.93 | 129.45 | 115.56 | 144.91 | 164.64 |
Other Operating Expenses | 16.65 | 15.79 | 11.67 | 9.43 | 11.71 | 26.73 |
Operating Expenses | 471.17 | 463.06 | 475.26 | 456.65 | 582.06 | 765.17 |
Operating Income | -101.52 | -103.14 | -131.53 | -267.47 | 98.14 | 117.18 |
Interest Expense | -25.36 | -27.25 | -28.8 | -37.76 | -36.55 | -21.89 |
Interest & Investment Income | 163.98 | 106.42 | 64.63 | 68.13 | 33.47 | 36.34 |
Currency Exchange Gain (Loss) | -26.13 | -26.13 | 35.03 | 2.81 | 107.95 | -30.28 |
Other Non Operating Income (Expenses) | -24.31 | -1.65 | -2.02 | -1.85 | -2.4 | -1.03 |
EBT Excluding Unusual Items | -13.34 | -51.74 | -62.68 | -236.15 | 200.62 | 100.31 |
Impairment of Goodwill | - | - | -208.47 | -107.69 | -46.73 | - |
Gain (Loss) on Sale of Investments | -33.89 | -31.97 | -35.24 | -117.62 | -45.68 | 6.46 |
Gain (Loss) on Sale of Assets | 0.45 | 0.03 | 1.04 | 12.88 | 0.29 | -1.48 |
Asset Writedown | -22.27 | 1.57 | -34.38 | -25.13 | -13.42 | 0.55 |
Other Unusual Items | -1.53 | -1.99 | 2.86 | 7.5 | 5.73 | 17.18 |
Pretax Income | -70.58 | -84.09 | -336.88 | -466.22 | 100.8 | 123.03 |
Income Tax Expense | 5.19 | 9.66 | -2.99 | -44.64 | 14.73 | 29.17 |
Earnings From Continuing Operations | -75.76 | -93.75 | -333.89 | -421.58 | 86.08 | 93.87 |
Minority Interest in Earnings | 1.91 | 2.68 | 3.62 | 1.53 | 1.94 | 1.36 |
Net Income | -73.86 | -91.08 | -330.27 | -420.06 | 88.01 | 95.23 |
Net Income to Common | -73.86 | -91.08 | -330.27 | -420.06 | 88.01 | 95.23 |
Net Income Growth | - | - | - | - | -7.58% | -70.21% |
Shares Outstanding (Basic) | 1,618 | 1,518 | 1,573 | 1,616 | 1,760 | 1,587 |
Shares Outstanding (Diluted) | 1,618 | 1,518 | 1,573 | 1,616 | 1,760 | 1,587 |
Shares Change (YoY) | 15.88% | -3.48% | -2.66% | -8.22% | 10.91% | -0.71% |
EPS (Basic) | -0.05 | -0.06 | -0.21 | -0.26 | 0.05 | 0.06 |
EPS (Diluted) | -0.05 | -0.06 | -0.21 | -0.26 | 0.05 | 0.06 |
EPS Growth | - | - | - | - | -16.67% | -70.00% |
Free Cash Flow | -153.37 | -134.14 | 52.73 | 87.46 | -63.33 | -127.2 |
Free Cash Flow Per Share | -0.10 | -0.09 | 0.03 | 0.05 | -0.04 | -0.08 |
Dividend Per Share | - | - | - | - | 0.050 | 0.100 |
Dividend Growth | - | - | - | - | -50.00% | 400.00% |
Gross Margin | 19.87% | 19.34% | 17.73% | 8.71% | 25.15% | 35.51% |
Operating Margin | -5.46% | -5.54% | -6.78% | -12.31% | 3.63% | 4.72% |
Profit Margin | -3.97% | -4.90% | -17.04% | -19.34% | 3.26% | 3.83% |
Free Cash Flow Margin | -8.24% | -7.21% | 2.72% | 4.03% | -2.34% | -5.12% |
EBITDA | 233.89 | 232.83 | 206.7 | 92.7 | 429.78 | 406.32 |
EBITDA Margin | 12.57% | 12.51% | 10.66% | 4.27% | 15.89% | 16.35% |
D&A For EBITDA | 335.4 | 335.97 | 338.23 | 360.17 | 331.64 | 289.14 |
EBIT | -101.52 | -103.14 | -131.53 | -267.47 | 98.14 | 117.18 |
EBIT Margin | -5.46% | -5.54% | -6.78% | -12.31% | 3.63% | 4.72% |
Effective Tax Rate | - | - | - | - | 14.61% | 23.71% |
Revenue as Reported | 1,861 | 1,861 | 1,938 | 2,172 | 2,704 | 2,485 |
Advertising Expenses | - | 3.72 | 2.99 | 2.79 | 0.21 | 0.64 |